In recent years, with the advent of molecular-targeted drugs and immune checkpoint inhibitors for lung cancer therapy, testing for genetic mutation and programmed cell death ligand-1 (PD-L1) of bronchoscopic specimens has become increasingly important. This evidence concerns the gene CD274 and lung cancer.